Mineralys Therapeutics, Inc. (NasdaqGS: MLYS)
Health Care · Biotechnology · US
$23.37
-1.10% today · -45.7% 1Y
Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.07B and employs 76 people.
Over the last twelve months the share price has lost 45.7%, trading between 21.46 and 47.65.
Tweenvest scores Mineralys Therapeutics, Inc. across four factors: quality 39/100, value 52/100. Its strongest factor is value.
MLYS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.07B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.38
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- $47.65
- 52-week low
- $21.46
- Avg volume (3M)
- —
- Shares outstanding
- 88.41M
- Employees
- 76
- Next earnings
- —
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
- ISIN
- US6031701013
- Founded
- 2019
- Listed since
- Feb 10, 2023
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | $2.12B | CN¥8.53 | +1.79% |
| Viridian Therapeutics, Inc.NasdaqCM: VRDN | $2.11B | $18.66 | -3.81% |
| Duality Biotherapeutics, Inc.SEHK: 9606 | $2.11B | HK$182.70 | -6.64% |
| Novavax, Inc.NasdaqGS: NVAX | $2.10B | $12.69 | -0.47% |
| AlvotechNasdaqGM: ALVO | $2.06B | $5.87 | +1.56% |
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.10 | -0.12% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.02B | CN¥37.86 | -4.97% |
Figures last refreshed Oct 11, 2026.